Peripheral Nerve Injuries
0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Neuraptive TherapeuticsNTX-001
Tulavi TherapeuticsNerve Cap
Integra LifeSciencesNeuraGen
Clinical Trials (3)
Total enrollment: 1,068 patients across 3 trials
Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries
Start: Sep 2020Est. completion: Jun 202451 patients
Phase 2Completed
Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study
Start: Jan 2026Est. completion: May 20291,000 patients
N/ANot Yet Recruiting
REINVENT Registry (Registry of the Nerve Gap Repair From Integra)
Start: May 2022Est. completion: Jun 202417 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.